pharmacodynamics of antidepressants...2015/11/13 · learning objectives after completing this...
TRANSCRIPT
![Page 1: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/1.jpg)
Pharmacodynamics of
AntidepressantsJose de Leon, MD
(11-13-15)http://www.ncbi.nlm.nih.gov/pubmed/25196459
![Page 2: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/2.jpg)
Learning ObjectivesAfter completing this presentation, the participant should
be able to:
1) Appreciate the relevance of pharmacodynamics for
antidepressant efficacy.
2) Appreciate the relevance of pharmacodynamics for
antidepressant safety.
3) Summarize frequent adverse drug reactions (ADRs)
including a) sleepiness/ insomnia, b) weight changes,
c) withdrawal symptoms, d) sexual ADRs, and e)
gastro-intestinal ADRs.
4) Remember that, on rare occasions, antidepressants can
kill your patients by contributing to arrhythmias,
serotonin syndrome or hemorrhages.
![Page 3: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/3.jpg)
WarningThis is an extraordinarily long presentation:
1) You may need to read it more than once until you have
become familiar with key aspects. More importantly,
you need to practice every day and review the pharma-
dynamics of drugs when any of your patients are
taking antidepressants in the context of polypharmacy.
2) Our understanding of brain pharmacodynamics is
limited; therefore, there are many disagreements in the
literature. In the process of summarizing, Dr. de Leon
had to made arbitrary decisions with which other
authors may not agree.
3) As Dr. de Leon is not an expert in this area, for the
“Do Not Forget” Section, he selected a recent review
on frequent ADRs in primary care.
![Page 4: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/4.jpg)
Abbreviations■ ADH: antidiuretic hormone
■ ADHD: attention deficit-hyperactivity disorder
■ ADR: adverse drug reaction
■ DDI: drug-drug interaction
■ GI: gastro-intestinal
■ HERG: ether-a-go-go-related gene
■ OCD: obsessive-compulsive disorder
■ SIADH: syndrome of inappropriate ADH secretion
Neurotransmission
■ 5HT: serotonin
■ α: alpha adrenergic
■ H: histamine
■ M: muscarinic
■ MT: melatonin
■ norepinephrine=noradrenaline. Not abbreviated.
![Page 5: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/5.jpg)
Abbreviations for Antidepressants
■ Antidepressants that are not included:□ MAOIs: monoamine oxidase inhibitors □ nefazadone
■ This presentation focuses on:□ TCAs: tricyclic antidepressants, and□ newer compounds:
● SNRIs: serotonin-norepinephrine inhibitors
● SSRIs: selective serotonin reuptake inhibitors
● Others: the rest
![Page 6: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/6.jpg)
Lecture Content
1. Efficacy 2. Safety3. Pharmacokinetics:
Facilitator of Pharmacodynamics
4. “Do Not Forget” Section
![Page 7: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/7.jpg)
1. Efficacy 1.1. Depression 1.2. OCD1.3. Anxiety1.4. Pain1.5. Weight Loss1.6. Smoking Cessation1.7. ADHD1.8. Insomnia1.9. Cataplexy1.10. Some Types of Urinary Incontinence1.11. Menopausal Vasomotor Symptoms
Lecture Content on Efficacy
![Page 8: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/8.jpg)
2.1. Brain 2.2. Periphery (with/without brain)
Lecture Content on Safety
![Page 9: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/9.jpg)
2.1. Brain 2.1.1. Weight Gain
2.1.2. ↓ Seizure Threshold
2.1.3. ↓ Dopaminergic Activity
2.1.4. Psychotic Exacerbation
2.1.5. Insomnia
2.1.6. Sedation
2.1.7. Memory Impairment
Lecture Content on Safety: Brain Mechanisms
![Page 10: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/10.jpg)
2.2.1. Nausea and Vomiting
2.2.2. Tachycardia and/or Hypertension
2.2.3. Orthostatic Hypotension
2.2.4. Diarrhea
2.2.5. Sexual ADRs
2.2.6. Hyperlipidemia
2.2.7. Anticholinergic Symptoms
2.2.8. Urinary Symptoms
2.2.9. Mydriasis
2.2.10. Hyperhydrosis
2.2.11. Osteoporosis
2.2.12. Discontinuation/Withdrawal Syndrome
2.2.13. Risk for Bleeding
2.2.14. Serotonin Syndrome
2.2.15. Arrhythmias
2.2.16. Neutropenia
2.2.17. Hyponatremia
2.2.18. Liver Injury
Lecture Content on Safety: Periphery Mechanisms
![Page 11: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/11.jpg)
1. Pharmacodynamics
of Antidepressant
Efficacy
![Page 12: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/12.jpg)
1. Pharmacodynamics of Antidepressant Efficacy
1.1. Depression
1.2. OCD
1.3. Anxiety
1.4. Pain
1.5. Weight Loss
1.6. Smoking Cessation
1.7. ADHD
1.8. Insomnia
1.9. Cataplexy
1.10. Some Types of Urinary Incontinence
1.11. Menopausal Vasomotor Symptoms
![Page 13: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/13.jpg)
1.1. Depression
![Page 14: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/14.jpg)
1.1. Depression
■ Textbooks
□ usually report that the majority of antidepressants act by
inhibiting the reuptake of transporters,
□ but they also usually acknowledge that this is not a
definitively proven theory, since the chronology of reuptake
inhibition does not match the chronology of antidepressant
response.
■ Even less agreement is found concerning the mechanism
of action of:
□ mirtazapine, or
□ trazadone.
![Page 15: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/15.jpg)
1.1. Mechanism of Action: Transporters
■ Inhibitors of noradrenaline and serotonin transporters:
□ Desvenlafaxine, duloxetine and venlafaxine
□ Levomilnacipran and milnacipran (not in the USA)
□ TCAs
■ Selective inhibitors of the serotonin transporter: SSRIs
■ Selective inhibitors of the serotonin transporter and
serotonin receptor antagonists
□ Vilazodone: partial agonism of the 5-HT1A receptor.
□ Vortioxetine: ● antagonist: 5-HT3A and 5-HT7
● partial agonist: 5-HT1B
● agonist: 5-HT1A
■ Inhibitor of noradrenaline and dopamine transporters:
□ Bupropion
■ Selective inhibitor of noradrenaline transporter: Reboxetine
(not in the USA)
![Page 16: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/16.jpg)
1.1. Mechanism of Action: Others
■ Trazadone: □ 5-HT2 antagonist, and
□ m-CPP (its major metabolite): 5-HT2C agonist
■ Mirtazapine: □ α2 adrenergic receptor antagonist and/or
□ 5-HT2A and 5-HT2C antagonist
■ Agomelatine (not in the USA):
□ Melatonergic analogue (MT1/MT2 agonist) and
□ 5-HT2C antagonist
![Page 17: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/17.jpg)
1.2. OCD
![Page 18: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/18.jpg)
1.2. OCD■ Inhibition of the serotonin transporter:
□ SSRIs: first line
Approved in USA: ● fluoxetine
● fluvoxamine
● paroxetine
● sertraline
□ Clomipramine
■ SNRIs (off-label):
□ Desvenlafaxine
□ Duloxetine
□ Venlafaxine
![Page 19: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/19.jpg)
1.3. Anxiety
![Page 20: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/20.jpg)
1.3. Anxiety
■ It is usually assumed the mechanism is
the same as for depression.
■ Specificity for specific disorders
is doubtful, but only some drugs have
been studied for approval.
![Page 21: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/21.jpg)
1.3.1. Generalized Anxiety Disorder
■ Approved in the USA:
□ Duloxetine
□ Escitalopram
□ Paroxetine
□ Venlafaxine
![Page 22: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/22.jpg)
1.3.2. Social Anxiety
■ Approved in the USA:
□ Paroxetine
□ Sertraline
□ Venlafaxine
![Page 23: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/23.jpg)
1.3.3. Panic Disorder
■ Approved in the USA:
□ Paroxetine
□ Sertraline
□ Venlafaxine
■ TCAs:effective but off-label
![Page 24: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/24.jpg)
1.3.3. Panic Disorder
■ Second-generation antidepressant meta-analysis:
http://www.ncbi.nlm.nih.gov/pubmed/23111544
□ superior to placebo for panic symptoms:
citalopram>sertraline>paroxetine>fluoxetine>venlafaxine
□ superior to placebo for overall anxiety symptoms:
paroxetine>fluoxetine>fluvoxamine>citalopram>venlafaxine
>mirtazapine
□ lower drop-outs than placebo:
>venlafaxine>fluoxetine>sertraline>paroxetine>citalopram>
mirtazapine
□ not different from placebo in drop-outs:
fluvoxamine and reboxetine
![Page 25: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/25.jpg)
1.4. Pain
![Page 26: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/26.jpg)
1.4. Pain
■ Inhibition of the noradrenalin transporter:
appears more important.
■ TCAs: frequently used (off-label)
■ Approved in the USA for fibromyalgia:
□ Duloxetine
□ Milnacipran
■ Duloxetine is also approved in the USA for:
□ Diabetic peripheral neuropathy
□ Chronic musculoskeletal pain
![Page 27: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/27.jpg)
1.5. Migraine
Prophylaxis
![Page 28: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/28.jpg)
1.5. Migraine Prophylaxis
■ Mechanism of action: unknown.
■ Off-label in the USA:
□ TCAs: amitriptyline (better studied)
□ Venlafaxine: less data
![Page 29: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/29.jpg)
1.6. Weight Loss
![Page 30: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/30.jpg)
1.6. Weight Loss
■ Bupropion:
inhibition of dopamine transporter
□ Off-label in the USA
□ In combination with naltrexone, it is
approved in the USA for obesity.
■ Fluoxetine: some weight loss,
according to meta-analysis:
limited to the acute phase of treatment.http://www.ncbi.nlm.nih.gov/pubmed/21062615
![Page 31: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/31.jpg)
1.7. Smoking Cessation
![Page 32: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/32.jpg)
1.7. Smoking Cessation
■ Bupropion:
inhibition of dopamine transporter
![Page 33: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/33.jpg)
1.8. ADHD
![Page 34: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/34.jpg)
1.8. ADHD
■ Bupropion:
□ Inhibition of noradrenergic and
dopamine transporters
□ Off-label in the USA
□ Superior to placebo in adults
http://www.ncbi.nlm.nih.gov/pubmed/22176279
■ Other antidepressants: very limited data
![Page 35: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/35.jpg)
1.9. Insomnia
![Page 36: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/36.jpg)
1.9. Insomnia
■ Antagonism of brain H1 receptors
(daily sedation can be a problem)
All drugs are off-label in the USA:
□ Amitriptyline
□ Mirtazapine
□ Trazadone
■ Agonism of brain MT2 receptors
□ Agomelatine (not approved in the USA)
![Page 37: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/37.jpg)
1.10. Cataplexy
![Page 38: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/38.jpg)
1.10. Cataplexy
■ Suppression of REM sleep:
Off-label in the USA:
□ TCAs
□ Venlafaxine
![Page 39: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/39.jpg)
1.11. Some Types of
Urinary Incontinence
![Page 40: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/40.jpg)
1.11. Some Types of Urinary Incontinence
■ Noradrenergic mechanisms are important.
■ Stress urinary incontinence:
□ Duloxetine: off-label in the USA
■ Nocturnal enuresis in children:
□ Imipramine
![Page 41: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/41.jpg)
1.12. Menopausal
Vasomotor Symptoms
![Page 42: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/42.jpg)
1.12. Menopausal Vasomotor Symptoms
■ Including:
□ Hot flashes
□ Night sweats
■ Off-label in the USA
□ SNRIs
□ SSRIs
![Page 43: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/43.jpg)
2. Pharmacodynamics
of Antidepressant
Safety
![Page 44: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/44.jpg)
2. Pharmacodynamics of Antidepressant Safety
2.1. Brain
2.2. Periphery (with/without brain)
![Page 45: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/45.jpg)
2.1. Brain
Pharmacodynamics
of Antidepressant
Safety
![Page 46: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/46.jpg)
2.1. Brain Pharmacodynamics of Antidepressant Safety
2.1.1. Weight Gain
2.1.2. ↓ Seizure Threshold
2.1.3. ↓ Dopaminergic activity
2.1.4. Psychotic Exacerbation
2.1.5. Insomnia
2.1.6. Sedation
2.1.7. Memory Impairment
![Page 47: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/47.jpg)
2.1.1. Weight Gain
![Page 48: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/48.jpg)
2.1.1. Weight Gain■ Mechanism: ↑ appetite
□ TCAs: H1 & M antagonistsAmitriptyline (worst)
□ Mirtazapine: H1 & 5HT2C antagonist□ Paroxetine: H1antagonist
■ Agomelatine: 5HT2C antagonist□ Not enough long-term data □ Case reports: associated with weight
gain
![Page 49: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/49.jpg)
2.1.2.
↓ Seizure Threshold
![Page 50: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/50.jpg)
2.1.2. ↓ Seizure Threshold
■ Unknown mechanism
■ Versus placebo: http://www.ncbi.nlm.nih.gov/pubmed/17223086
□ Worse:● Bupropion
● TCAs
□ Better: other newer compounds
■ Fluoxetine:
□ Anti-seizure activity: animal
models
□ Seizures: according to case reports
![Page 51: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/51.jpg)
2.1.3.
↓ Dopaminergic Activity
![Page 52: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/52.jpg)
2.1.3. ↓ Dopaminergic Activity
■ Mechanism not well understood.
■ ↓ Dopaminergic activity manifests as:
□ Akathisia (rare): SSRIs
□ Other extrapyramidal symptoms
(rare): all antidepressants
□ Hyperprolactinemia (rare):
probably all antidepressants
![Page 53: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/53.jpg)
2.1.4. Psychotic
Exacerbations
![Page 54: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/54.jpg)
2.1.4. Psychotic Exacerbations
■ Rare and manifest as:
□ New psychotic episodes
□ Psychotic exacerbations
■ Described in connection with:
□ Bupropion: inhibition of dopamine
transporter
□ TCAs: unknown mechanism
![Page 55: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/55.jpg)
2.1.5. Insomnia
![Page 56: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/56.jpg)
2.1.5. Insomnia
■ In all new antidepressants
except agomelatine.
■ Mechanisms:
□ Stimulation 5HT2: SSRIs
□ Blockade noradrenaline transporter:
● Bupropion
● Reboxetine
● SNRIs
□ ↑ Noradrenergic activity: high doses
of mirtazapine.
![Page 57: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/57.jpg)
2.1.6. Sedation
![Page 58: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/58.jpg)
2.1.6. Sedation
■ Antidepressants used to treat insomnia
can cause sedation.
■ Mechanism:
□ H1 antagonism:
● TCAs
● Mirtazapine
● Trazadone
□ MT2: agonism
● Agomelatine (not in the USA)
![Page 59: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/59.jpg)
2.1.7. Memory
Impairment
![Page 60: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/60.jpg)
2.1.7. Memory Impairment
■ Mechanism: blockade of brain Mreceptors
■ Blockade of M1 and M2 receptors has been associated with impairedlearning and memory in animal studies.
■ Potent compounds in high doses or in vulnerable patients (demented)can cause confusion/delirium.
![Page 61: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/61.jpg)
2.1.7. Muscarinic Blockade
■ High potency: □ Amitriptyline □ Clomipramine □ Protriptyline
■ Moderate potency: □ Doxepin□ Imipramine□ Nortriptyline □ Trimipramine
■ Low potency (relevant only in high doses):□ Amoxapine□ Desimipramine □ Maprotiline □ Mirtazapine □ Paroxetine
![Page 62: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/62.jpg)
2.1.7. Muscarinic Blockade: Unclear
■ Anti-muscarinic activity is seen in some studies, but not in others:
□ Citalopram□ Escitalopram □ Fluoxetine□ Sertraline □ Trazadone
![Page 63: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/63.jpg)
2.2. Peripheral
Pharmacodynamics
of Antidepressant
Safety
![Page 64: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/64.jpg)
2.2. Peripheral Pharmacodynamics of Antidepressant Safety
2.2.1. Nausea and Vomiting
2.2.2. Tachycardia and/or Hypertension
2.2.3. Orthostatic Hypotension
2.2.4. Diarrhea
2.2.5. Sexual ADRs
2.2.6. Hyperlipidemia
2.2.7. Anticholinergic Symptoms
2.2.8. Urinary Symptoms
2.2.9. Mydriasis
2.2.10. Hyperhidrosis
2.2.11. Osteoporosis
2.2.12. Discontinuation/Withdrawal Syndrome
2.2.13. Risk for Bleeding
2.2.14. Serotonin Syndrome
2.2.15. Arrhythmias
2.2.16. Neutropenia
2.2.17. Hyponatremia
2.2.18. Liver Injury
![Page 65: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/65.jpg)
2.2.1. Nausea and Vomiting
![Page 66: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/66.jpg)
2.2.1. Nausea and Vomiting
■ Mechanism: inhibition of serotonin transporter.
■ Common in newer antidepressants;most frequent cause ofdiscontinuation in the first 30 days
![Page 67: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/67.jpg)
2.2.1. Nausea and Vomiting
■ Probably worse: □ Desvenlafaxine □ Duloxetine □ Venlafaxine
■ Probably intermediate: □ SSRIs□ Vilazodone□ Vortioxetine
■ Probably lower risk:□ Levomilnacipran□ Milnacipran
![Page 68: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/68.jpg)
2.2.1. Nausea and Vomiting
■ Be aware:□ mirtazapine, and□ TCAsmay help with some nausea and have been used for “psychogenic vomiting”.
![Page 69: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/69.jpg)
2.2.2. Tachycardia
and/or
Hypertension
![Page 70: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/70.jpg)
2.2.2. Tachycardia and/or Hypertension
■ Probable mechanism:
inhibition of noradrenalin transporter
■ Rare in RCTs.TCAs are associated with hypertension inpharmacoepidemiology studies.
■ Review on hypertension: http://www.ncbi.nlm.nih.gov/pubmed/18652794
□ Venlafaxine: definitively associated□ Desvenlafaxine and milnacipran:
also associated□ Duloxetine: be cautious in hypertensive patients.
![Page 71: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/71.jpg)
2.2.3. Orthostatic
Hypotension
![Page 72: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/72.jpg)
2.2.3. Orthostatic Hypotension
■ Mechanism: blockade α1■ Tolerance is important and can be avoided
by titration.■ Definitively associated with:
□ TCAs □ Trazadone
■ Mirtazapine: □ Very low α1 affinity□ Rarely associated with syncope
■ Venlafaxine: □ No α1 affinity□ Associated with orthostatic changes
in geriatric patients
![Page 73: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/73.jpg)
2.2.4. Diarrhea
![Page 74: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/74.jpg)
2.2.4. Diarrhea
■ Mechanism: unknown
■ Definitively more frequent with:□ Sertraline
■ Others: □ Vilazodone □ Vortioxetine
![Page 75: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/75.jpg)
2.2.5. Sexual ADRs
![Page 76: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/76.jpg)
2.2.5. Sexual ADRs
■ Serotoninergic mechanisms:□ Stimulation of 5TH2 and 5TH3
□ Effect of serotonin on nitric oxide production
■ ♀: □ ↓ Libido □ Others
■ ♂: □ Erectile dysfunction □ Problems with orgasm□ ↓ Libido
![Page 77: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/77.jpg)
2.2.5. Sexual ADRs■ Frequent:
□ SNRIs□ SSRIs□ TCAs
■ > Placebo: □ Vilazodone□ Vortioxetine
■ Very low risk: □ Agomelatine□ Reboxetine
■ No different than placebo: □ Bupropion□ Mirtazapine
![Page 78: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/78.jpg)
2.2.5. Sexual ADRs: Priapism
■ It is rare but does occur with trazadone.
■ Blockade α1 (& α2) in periphery
![Page 79: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/79.jpg)
2.2.6. Hyperlipidemia
![Page 80: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/80.jpg)
2.2.6. Hyperlipidemia:
■ Indirect: Weight-mediated
■ Direct in lipid metabolism:□ Mirtazapine
![Page 81: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/81.jpg)
2.2.7. Anticholinergic
Symptoms
![Page 82: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/82.jpg)
2.2.7. Anticholinergic Symptoms
■ Antimuscarinic symptoms■ Blockade of peripheral M receptors■ Symptoms:
□ Tachycardia: M2 heart □ Constipation: M3 colon□ Dry mouth: M1 and M3 salivary
glands □ Urinary retention: M3 detrusor
muscle in bladder □ Blurred vision: M3 eye
http://www.ncbi.nlm.nih.gov/pubmed/21495973
![Page 83: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/83.jpg)
2.2.7. Muscarinic Blockade
■ High potency: □ Amitriptyline □ Clomipramine□ Protriptyline
■ Moderate potency: □ Doxepin □ Imipramine □ Nortriptyline □ Trimipramine
■ Low potency (relevant only in high doses):□ Amoxapine□ Desimipramine □ Maprotiline □ Mirtazapine □ Paroxetine
![Page 84: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/84.jpg)
2.2.7. Muscarinic Blockade: Unclear■ In some studies anti-muscarinic activity but not in others:
□ Citalopram□ Escitalopram □ Fluoxetine□ Sertraline □ Trazadone
■ Reboxetine: □ Can cause: ● Dry mouth
● Constipation● Urinary retention, on rare occasions
□ It is believed affinity for muscarinic receptors is too low. □ No anti-muscarinic metabolites have been identified.□ These symptoms may occur through noradrenergic
mechanisms.
![Page 85: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/85.jpg)
2.2.7. Risk for Heat Stroke
■ Potent anti-muscarinic TCAs:↓ sweating
■ Rare but potentially lethal (elderly)
■ Other risk factors:
□ Polypharmacy (additive effects):
● Antipsychotic: temperature regulation
● Topiramate/zonisamide: ↓ sweating
by inhibition of carbonic anhydrase
□ After heat exposure:
● High temperatures in summer, or
● Intense exercise
![Page 86: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/86.jpg)
2.2.8. Urinary Symptoms
![Page 87: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/87.jpg)
2.2.8. Urinary Symptoms
■ Symptoms:□ Dysuria □ Urinary retention□ Sensation of incomplete bladder
emptying■ Mechanisms: noradrenergic■ Antidepressants:
□ SNRIs□ Reboxetine
![Page 88: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/88.jpg)
2.2.9. Mydriasis
![Page 89: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/89.jpg)
2.2.9. Midryasis
■ Risk for patients with uncontrolled narrow-angle glaucoma
■ Mechanisms: inhibition of noradrenergic transporter
■ Antidepressants:□ SNRIs□ Reboxetine□ TCAs
![Page 90: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/90.jpg)
2.2.10. Hyperhidrosis
![Page 91: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/91.jpg)
2.2.10. Hyperhidrosis
■ Frequency:□ Uncommon in all antidepressants□ Common (5-14%) in SSRIs or SNRIs,
according to a recent articlehttp://www.ncbi.nlm.nih.gov/pubmed/23638448
■ Mechanisms: □ Peripheral noradrenergic □ Central serotonergic
■ Treatment:□ Terazosin: α1 blocker (be careful
with orthostatic hypotension)http://www.ncbi.nlm.nih.gov/pubmed/23638448
![Page 92: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/92.jpg)
2.2.11. Osteoporosis
![Page 93: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/93.jpg)
2.2.11. Osteoporosis
■ After many years of treatment:□ Not well-studied□ Associated with SSRIs in
pharmacoepidemiological studies
■ Mechanisms: □ Serotonergic mechanisms
in bone tissue
![Page 94: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/94.jpg)
2.2.12. Discontinuation/
Withdrawal Syndrome
![Page 95: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/95.jpg)
2.2.12. Discontinuation/Withdrawal Syndromes
2.2.12.1. Newer Compounds
2.2.12.2. TCAs: Cholinergic
Rebound
![Page 96: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/96.jpg)
2.2.12.1. Discontinuation
Syndrome: Newer Compounds
![Page 97: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/97.jpg)
2.2.12.1. Discontinuation Syndrome: Newer Compounds
■ Frequency: □ High: paroxetine and venlafaxine□ Intermediate: others □ Very rare if it exists: fluoxetine
due to long half-life■ Absent:
□ Agomelatine□ Reboxetine
![Page 98: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/98.jpg)
2.2.12.1. Discontinuation Syndrome: Newer Compounds
■ Mechanisms: not well-understood■ Most frequent:
□ Acute headaches□ Dizziness □ Nausea
■ Others: □ Lethargy and sleep disturbances□ Psychological symptoms:
● Anxiety● Agitation● Irritability ● Poor concentration
![Page 99: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/99.jpg)
2.2.12.1. Withdrawal Syndrome: Newer Compounds
■ The literature is confusing.
■ Chouinard & Chouinard proposed a new classification with diagnostic criteria. http://www.ncbi.nlm.nih.gov/pubmed/25721565
After SSRI or SNRI withdrawal:□ New withdrawal symptoms □ Rebound withdrawal□ Persistent post-withdrawal disorder
![Page 100: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/100.jpg)
2.2.12.2. TCAs:
Cholinergic Rebound
![Page 101: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/101.jpg)
2.2.12.2. Cholinergic Rebound: TCAs
■ Mechanisms: □ Sudden discontinuation of TCAs□ Cholinergic rebound due to lack of
muscarinic blockade■ Symptoms:
□ Nausea/vomiting □ Diarrhea□ Diaphoresis □ Restlessness □ Insomnia
■ They respond to anticholinergic drugs.
![Page 102: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/102.jpg)
2.2.13. Risk for Bleeding
![Page 103: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/103.jpg)
2.2.13. Risk for Bleeding; SSRIs
■ Rare but potentially lethal■ It can happen with SSRIs without
any other risk http://www.ncbi.nlm.nih.gov/pubmed/22424167
■ Typically in combination:□ Drugs with hemorrhagic risk□ Surgery□ Delivery
![Page 104: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/104.jpg)
2.2.13. Risk for Bleeding
■ Main mechanism: □ Serotonin depletion at platelets
due to inhibition of serotonin transporter
■ Other mechanisms: http://www.ncbi.nlm.nih.gov/pubmed/21190637
□ ↑ Gastric acid secretion: for upper gastrointestinal bleeding
□ ↓ Ischemic heart disease● ↓ Platelet reactivity● ↓ Endothelial reactivity● Inflammatory markers
![Page 105: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/105.jpg)
2.2.14. Serotonin Syndrome
![Page 106: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/106.jpg)
2.2.14. Serotonin Syndrome
■ Rare but potentially lethal.
■ Mechanism:↑ serotonin activity □ Central nervous system, and□ Periphery
■ Usually combinations ofserotonergic drugs
![Page 107: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/107.jpg)
2.2.14. Serotonin Syndrome
■ Main symptoms that warrant the diagnosis 1) Spontaneous clonus, 2) Inducible clonus with
agitation or diaphoresis, 3) Ocular clonus with
agitation or diaphoresis, or4) Tremor and hyperreflexia.
Hypertonia, T > 38oC (100.4oF)and ocular or inducible clonus
http://www.ncbi.nlm.nih.gov/pubmed/20433130 pdf available at PubMed.
■ Ocular clonus: slow, continuous, horizontal eye movements
![Page 108: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/108.jpg)
2.2.15. Arrhythmias
![Page 109: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/109.jpg)
2.2.15. Arrhythmias
2.2.15.1. Arrhythmias by TCAs
2.2.15.2. Torsades de Pointes
2.2.15.3. Risks for Brugada Syndrome
![Page 110: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/110.jpg)
2.2.15.1.
Arrhythmias
due to TCAs
![Page 111: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/111.jpg)
2.2.15.1. Arrhythmias due to TCAs
■ Blockade of heart sodiumrepolarizing channels
■ Manifests in:□ QRS widening □ QTc prolongation □ Ventricular arrhythmias
■ Dose-related:□ High serum concentrations □ An overdose can be lethal.
■ Narrow therapeutic window
![Page 112: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/112.jpg)
2.2.15.2.
Torsades de Pointes
![Page 113: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/113.jpg)
2.2.15.2. Torsades de Pointes
■ Blockade of heart potassiumrepolarizing channels which areencoded by the human ether-a-go-go-related gene (HERG).
■ Torsades de Pointes has beendescribed for:
□ Citalopram □ Fluoxetine □ Sertraline. http://www.ncbi.nlm.nih.gov/pubmed/25114780
![Page 114: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/114.jpg)
2.2.15.2. Torsades de Pointes
■ Most cases of drug-induced torsadesde pointes occur in the context ofsubstantial prolongation of the QTc interval, typically (>500 msec),but QTc alone is a relatively poorpredictor of arrhythmic risk in any individual patient.
■ Citalopram US prescribinginformation recommends against doses > 40 mg/day.
http://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CITALOPRAM
![Page 115: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/115.jpg)
2.2.15.2. Torsades de Pointes
■ The literature on clinical cases oftorsades de pointes is very complex.□ Cases frequently include
polypharmacy and DDIs with: ● A pharmacodynamic component:
multiple drugs with HERG channel inhibitory properties andsometimes
● A pharmacokinetic component: an inhibitor ↑ concentrations of one or several of the drugs
□ Other risk factors
![Page 116: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/116.jpg)
2.2.15.2. Torsades de Pointes
■ Other risk factors:
□ Geriatric age
□ Female gender
□ Bradycardia
□ Hypokalemia
□ Hypomagnesemia
■ Be careful when prescribing SSRIs
in patients with risk factors.
■ Be extremely careful when prescribing
SSRI-antipsychotic combinations in
patients with risk factors.
![Page 117: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/117.jpg)
2.2.15.3.
Brugada Syndrome
![Page 118: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/118.jpg)
2.2.15.3. Brugada Syndrome
■ Genetic channelopathy at heart repolarizing channels, either:□ Sodium □ Potassium □ Calcium
■ Characterized by:□ High incidence of ventricular
fibrillation and□ Specific ECG pattern:
● Pseudo right bundle branch block and
● Persistent ST elevation inV1 to V3.
![Page 119: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/119.jpg)
2.2.15.3. Brugada Syndrome
■ It is preferable to avoid:□ Fluoxetine □ Fluvoxamine □ Paroxetine
http://www.brugadadrugs.org/advisory-board/
![Page 120: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/120.jpg)
2.2.16. Neutropenia
![Page 121: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/121.jpg)
2.2.16. Neutropenia
■ Mechanism: unknown
■ Described with mirtazapine on rare occasions
![Page 122: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/122.jpg)
2.2.17. Hyponatremia
![Page 123: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/123.jpg)
2.2.17. Risk for Hyponatremia
■ Rare cases have been described with
all antidepressants, usually in
geriatric patients, particularly
females.
■ Mechanism:
□ SIADH and/or ↑ ADH sensitivity
□ It is not understood how
antidepressants can cause it.
![Page 124: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/124.jpg)
2.2.18. Liver Injury
![Page 125: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/125.jpg)
2.2.18. Liver Injury
2.2.18.1. ↑ Liver Enzymes
2.2.18.2. Life-Threatening
Liver Injury
![Page 126: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/126.jpg)
2.2.18.1.
↑ Liver Enzymes
![Page 127: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/127.jpg)
2.2.18.1. ↑ Liver Enzymes
■ Mechanism: unknown
■ Agomelatine:
□ Up to 5% in 50 mg/day
■ Other antidepressants:
□ Rare
![Page 128: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/128.jpg)
2.2.18.2.
Life-Threatening
Liver Injury
![Page 129: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/129.jpg)
2.2.18.2. Life-Threatening Liver Injury
■ Mechanism:
□ Immuno-allergy or
□ Toxicity from metabolites
■ Risk: http://www.ncbi.nlm.nih.gov/pubmed/24362450
□ Agomelatine>
□ Bupropion, duloxetine, TCAs>
□ Others>
□ Lowest: citalopram, escitalopram,
fluoxetine and paroxetine
![Page 130: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/130.jpg)
3. Pharmacokinetics
Facilitates
Pharmacodynamics
![Page 131: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/131.jpg)
3. Pharmacokinetics Facilitates Pharmacodynamics
■ Pharmacokinetics facilitates pharmacodynamics.
■ Efficacy:
□ Sufficient drug concentration may be needed.
□ Once there is sufficient drug concentration,
pharmacodynamics determines efficacy.
■ Safety:
□ ADRs are dose-related: sufficient concentration
at the action site may be needed.
Pharmacokinetics plays a facilitator role.
□ When ADRs are not dose-related: small
concentrations at the action site may be enough.
Pharmacokinetics may not be relevant.
![Page 132: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/132.jpg)
3. Pharmacokinetics Facilitates Pharmacodynamics
■ Pharmacodynamics probably determines specific
ADRs in a patient when concentrations at the site of
action are sufficient for “toxicity”.
Too-high drug concentrations (pharmacokinetics):
contribute to poor safety in general.
■ Pharmacodynamic factors probably determine
□ Whether ADRs develop or not
□ Which ADRs
![Page 133: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/133.jpg)
4. The “Do Not Forget”
Section
![Page 134: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/134.jpg)
4. The “Do Not Forget” Section
■ This is a very long and complex presentation:
□ Efficacy: list 11 possible reasons for prescription
□ Safety brain mechanisms: list 7 ADRs
□ Safety periphery mechanisms: list 18 ADRs
■ Dr. de Leon is not an expert in this area but decided
to select for the “Do Not Forget Section”:
□ Common ADRs of antidepressants commonly
prescribed in the USA
□ Possible lethal ADRs
□ Reflections on TCAs
![Page 135: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/135.jpg)
4. The “Do Not Forget” Section
4.1. Common ADRs of
Antidepressants Commonly
Prescribed in the USA
4.2. Possible Lethal ADRs
4.3. Reflections on TCAs
![Page 136: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/136.jpg)
4.1. Common ADRs of
Antidepressants Commonly
Prescribed in the USA
![Page 137: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/137.jpg)
4.1. Common ADRs
■ A recent US antidepressant trial in primary care:
□ included a “Depression Medication Choice” aid, and
□ studied 11 antidepressants:
● citalopram ● desvenlafaxine
● escitalopram ● duloxetine
● fluoxetine ● venlafaxine
● paroxetine ● bupropion
● sertraline ● mirtazapine
● amitriptyline or nortriptyline as TCAshttp://www.ncbi.nlm.nih.gov/pubmed/26414670
![Page 138: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/138.jpg)
4.1. Common ADRs
■ Provide ratings on 6 issues with “+s” or “-s”:
□ Sleep
□ Weight changes
□ Stopping approaches
□ Sexual issues
□ Costs
□ Keep in mind GI ADRs and other issues.
The take home patient leaflets are provided in supplemental
material http://archinte.jamanetwork.com/article.aspx?articleid=2443367
and are summarized in the next slides.
■ The “Depression Medication Choice” aid appears to Dr.
de Leon to be an updated reasonable summary of the most
frequent antidepressants used in the USA. Experts may
disagree on some of the details on ADRs.
![Page 139: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/139.jpg)
4.1. Common ADRs (Depression Medication Choice Aid)
4.1.1. Sleep
4.1.2. Weight Change
4.1.3. Stopping Approach
4.1.4. Sexual Issues
4.1.5. GI ADRs
4.1.6. Other Issues
![Page 140: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/140.jpg)
4.1.1. Sleep
(Depression Medication Choice Aid)
![Page 141: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/141.jpg)
4.1.1. Sleep (Depression Medication Choice Aid)
■ Insomnia/sleepiness:
□ Insomnia: ++: ● bupropion
□ Sleepiness: ++: ● mirtazapine
● TCAs
![Page 142: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/142.jpg)
4.1.2. Weight Change
(Depression Medication Choice Aid)
![Page 143: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/143.jpg)
4.1.2. Weight Change (Depression Medication Choice Aid)
■ Weight:
□ Gain: ++++: ● escitalopram
● paroxetine
● mirtazapine
● TCAs
+++: ● citalopram
++: ● duloxetine
● venlafaxine
+: ● sertraline
□ Loss: -: ● duloxetine
--: ● bupropion
![Page 144: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/144.jpg)
4.1.3. Stopping Approach
(Depression Medication Choice Aid)
![Page 145: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/145.jpg)
4.1.3. Stopping Approach (Depression Medication Choice Aid)
■ Quitting will make you sick:
+++: ● paroxetine (sickness if you skip)
● venlafaxine (sickness if you skip)
+: ● citalopram
● escitalopram
● fluvoxamine
● sertraline
● desvenlafaxine (some risk of sickness if you skip)
● duloxetine (some risk of sickness if you skip)
● bupropion
● mirtazapine
● TCAs
■ No risk: ● fluoxetine
![Page 146: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/146.jpg)
4.1.4. Sexual Issues
(Depression Medication Choice Aid)
![Page 147: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/147.jpg)
4.1.4. Sexual Issues (Depression Medication Choice Aid)
■ Libido: □ Less: ---: ● paroxetine
--: ● TCAs-: ● citalopram
● escitalopram ● fluoxetine ● fluvoxamine● sertraline● desvenlafaxine ● duloxetine ● venlafaxine ● mirtazapine
□ More: ++: ● bupropion
![Page 148: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/148.jpg)
4.1.5. GI ADRs
(Depression Medication Choice Aid)
![Page 149: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/149.jpg)
4.1.5. GI ADRs (Depression Medication Choice Aid)
■ Fluvoxamine: more likely to causeconstipation, diarrhea or nausea
■ Sertraline: more likely to cause diarrhea
■ Venlafaxine: more likely to cause nausea/vomiting
■ TCAs: more likely to cause constipation, diarrhea or nausea
![Page 150: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/150.jpg)
4.1.6. Other Issues
(Depression Medication Choice Aid)
![Page 151: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/151.jpg)
4.1.6. Other Issues (Depression Medication Choice Aid)
■ Citalopram: risk of QTc prolongation■ Fluoxetine: DDIs (inhibit other drugs) ■ Fluvoxamine: no US approval for depression■ Paroxetine: risk of teratogenicity ■ Desvenlafaxine: hypertension issues ■ Duloxetine: hypertension issues
can help ease pain ■ Venlafaxine: hypertension and cardiac issues■ Bupropion: higher risk of seizure ■ Mirtazapine: starts to work more quickly■ TCAs: can help ease pain
not a good choice for the elderly
![Page 152: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/152.jpg)
4.2. Possible Lethal ADRs
![Page 153: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/153.jpg)
4.2. Possible Lethal ADRs
■ Dr. de Leon has reviewed >600 deaths at Kentucky
state mental health facilities since 2002:
□ Antipsychotics occasionally cause deaths.
□ Mood stabilizers occasionally cause deaths.
□ Antidepressants have not caused deaths.
There was not clear case of overdose only by
TCAs but TCAs are rarely prescribed.
■ Antidepressants can contribute to deaths through:
□ Arrhythmias
□ Serotonin syndrome
□ Hemorrhages
![Page 154: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/154.jpg)
4.3. Reflections on TCAs
![Page 155: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/155.jpg)
4.3. Reflections on TCAs
■ TCAs are rarely used as antidepressants by
non-psychiatrists.
■ Thus, TCA expertise may be a “niche”
skill that psychiatrists need to master.
If you use TCAs, you need expertise on:
□ ADRs: many are dose-related, including
risk for arrhythmias
□ TCA pharmacokinetics, including:
● CYP2D6 and CYP2C19 genotyping
● TDM
See “Antidepressant Pharmacokinetics”.
![Page 156: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/156.jpg)
References for Antidepressant Pharmacodynamics
l) 2014 article http://www.ncbi.nlm.nih.gov/pubmed/25196459 with
pdf http://uknowledge.uky.edu/psychiatry_facpub/40/ has the best
figures for all antidepressant pharmaco-
dynamics and focuses on AED DDIs.
2) 2014 article http://www.ncbi.nlm.nih.gov/pubmed/24494611 with
pdf http://uknowledge.uky.edu/psychiatry_facpub/42/ focuses on
DDIs between second-generation
antidepressants and second-generation
antipsychotics.
![Page 157: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/157.jpg)
Questions
-Please review the 10 questions in the pdf titled
“Questions on the Presentation: Pharmacodynamics of
Antidepressants”.
-You will find the answers on the last slide after the “Thank
you” slide. No peeking until you have answered all
the questions.
-If you do not answer all the questions correctly, please
review the Power Point presentation once again
to reinforce the pharmacological concepts.
![Page 158: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/158.jpg)
Thank you
![Page 159: Pharmacodynamics of Antidepressants...2015/11/13 · Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of pharmacodynamics](https://reader034.vdocument.in/reader034/viewer/2022051806/60001bf181a02a715853d2eb/html5/thumbnails/159.jpg)
Answers
1. A 6. A
2. D 7. D
3. D 8. D
4. A 9. D
5. C 10. A